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Abstract
The transcription factor SOX2, associated with amongst others OCT3/4, is essential for maintenance of pluripotency and self-
renewal of embryonic stem cells. SOX2 is highly expressed in embryonal carcinoma (EC), the stem cell component of
malignant nonseminomatous germ cell tumors, referred to as germ cell cancer (GCC). In fact, OCT3/4 together with SOX2 is
an informative diagnostic tool for EC in a clinical setting. Several studies support the hypothesis that SOX2 is a relevant
oncogenic factor in various cancers and recently, SOX2 has been suggested as a putative therapeutic target for early stage
EC. We demonstrate the presence of genomic amplification of SOX2 in an EC cell line, NCCIT, using array comparative
genome hybridization and fluorescence in situ hybridization. Down-regulation of SOX2 by targeted siRNA provokes NCCIT
cells towards apoptosis, while inhibition of OCT3/4 expression induced differentiation, with retained SOX2 levels. Mice
pluripotent xenografts from NCCIT (N-NCCIT and N2-NCCIT) show a consistent SOX2 expression, in spite of loss of the
expression of OCT3/4, and differentiation, with retained presence of genomic amplification. No SOX2 amplification has been
identified in primary pure and mixed EC in vivo patient samples so far. The data presented in this study are based on a single
EC cell line with a SOX2 amplification, with NT2 as control EC cell line, showing no profound induction of apoptosis upon
SOX2 downregulation. The findings are of relevance to identify mechanisms involved in the pathogenesis of EC tumors, and
support the model of SOX2-oncogene dependency of EC, which however, does not exclude induction of differentiation.
This finding is likely related to the presence of wild type p53 in GCC, resulting in expression of downstream target genes,
amongst others miR-34a, miR-145 and SOX2, associated to the unique sensitivity of GCC to DNA damaging agents.
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Introduction
SOX2 (sex-determining region Y-box2) is a 317 amino-acid
transcription factor containing an HMG domain located at 3q26,
being a critical transcription factor of normal embryonic stem (ES)
cell development and maintenance, as well as neural stem cells
[1,2]. During early embryogenesis, Sox2 is required for epiblast
maintenance, and formation of multipotent cell lineages in early
mouse development depends on Sox2 function [3]. Moreover,
Sox2 is one of the four transcription factors successfully used to
induce pluripotent stem cell (iPS) from mouse and human
fibroblast cells [4,5]. In particular, in these cells SOX2 physically
interacts with OCT3/4 and NANOG forming an interconnection
machinery that binds to promoters of numerous but defined stem
cell genes to induce their expression as well as repress expression of
genes related to differentiation [1].
This seems essential since generating iPS cells from primary
human fibroblast has become possible with the single use of
OCT3/4 and SOX2 [5]. Relative hyper- or hypo-expression
of these pluripotency factors may result in aberrant self-renewal of
ES cells and can possibly even promote oncogenesis [6]. Recent
studies have shown that SOX2 over-expression leads to aberrant
stem cell self-renewal signaling in breast cancer cells [7,8].
Moreover, several studies have shown over-expression of SOX2
in various cancers including glioblastoma [9], non-small cell lung
cancer [10,11], prostate cancer [12] and hepatocellular carcino-
mas [13] supporting SOX2 as a relevant oncogene in these
malignancies. Specifically, SOX2 is reported as a lineage-survival
oncogene in squamous cell carcinoma of the lung [14–16] and its
over-expression is associated with tumor progression and poor
clinical outcome in breast cancer [7,17]. These reports suggest that
SOX2 could activate important gene cascades involved in
initiation and progression of tumors and maintenance of a poorly
differentiated state [18].
Besides in these epithelial cancers, SOX2 has also been proven
to be of diagnostic value in the context of human germ cell cancers
(GCC) [19]. Testicular GCC originate from either a primordial
germ cell (PGC) or gonocyte during early development [20–22].
Histologically and clinically, GCC are classified into seminoma
(SE) and non-seminoma (NS). They both originate from the same
precursor known as carcinoma in situ (CIS), also referred to as
intratubular germ cell neoplasia unclassified (IGCNU) [20–22,23].
NS can contain both embryonal and extra-embryonal lineages,
including embryonal carcinoma (EC), somatic differentiation
(teratoma) and extra-embryonal differentiation (choriocarcinoma
(CH) and yolk sac tumor (YS)). EC is the malignant ES cell
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counterpart, in principle able to differentiate into virtually all tissue
lineages [24–26]. EC cells show a gene expression profile similar to
that of ES cells, including high expression of the core pluripotency
transcription factors OCT3/4 and SOX2. These transcription
factors act in concert to control stem cell self-renewal and
pluripotency [27,28]. OCT3/4 is expressed in CIS, SE and EC. In
contrast, SOX2 is expressed in EC but not the precursor lesions
and SE and normal germ cells. In addition, SOX2 can be
heterogeneously expressed in differentiated nonseminomatous
components. Currently, the expression of OCT3/4 and SOX2
are used for the diagnosis of EC while combination of the presence
of OCT3/4 and SOX17 is used for the diagnosis of SE [19].
Additionally, a single study [29] using an EC cell line NEC8 model
reported SOX2-siRNA induced apoptotic cell death in vitro and
growth suppression in vivo. In view of the similarity between EC
and human ES cells, disruption of the orchestrated activity of these
transcription factors could possibly induce lethal effects in EC cells
[29].
There are various cell lines representing EC tumors i.e. NTera2
(NT2) [30], NCCIT [31], and 2102Ep [32] in which OCT3/4
and SOX2 are highly expressed [33]. As a result of array
comparative genomic hybridization (CGH) on multiple EC cell
lines, NCCIT cell line, originating from a mediastinal GCC,
showed amplification at the long arm of chromosome 3, band q23
including the SOX2 gene locus [34]. In addition, it is shown that
NCCIT has no functional p53, while NT2 and 2102ep cell lines
contain wild type p53, expressed in a relative low and normal
level, respectively [35]. p53 is a transcription factor that plays a key
role in cellular defense mechanisms against neoplastic transfor-
mation, found to be mutated in a large number of human cancers,
for which GCC is an exception [36].
Moreover, it is shown that p53 plays an active role in promoting
differentiation of human ES cells and opposing self-renewal by
regulation of specific target genes and microRNAs (miRs). miRs
are small, non-coding RNAs of 21–23 nucleotides in length that
regulate gene expression, generally at a post-transcriptional level
[37]. Specific miRs regulate self-renewal and pluripotency in
human cells [38].
In this study we explored whether oncogene dependency of the
pluripotency gene SOX2 in EC exist, which might explain the
biological and clinical difference(s) between different histological
subtypes of GCC. Previously we have shown that reduction of
OCT3/4 and SOX2 in NT2 cause induction of differentiation
[33]. Here, we investigate the effect of reduction of OCT3/4 and
SOX2 by means of targeted siRNA in NCCIT cells. In addition,
in order to decipher whether specific amplification of pluripotency
genes associates with the undifferentiated state of EC, we
investigate whether primary GCC including pure EC and mixed
NS including EC components, have amplification of OCT3/4 and
SOX2 using Fluorescence In Situ hybridization (FISH).
Materials and Methods
Cell culture and manipulation
Both NT2 and NCCIT cell lines were received as gifts
[31,39,40]. NT2 and NCCIT cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Life technologies Europe BV,
Bleiswijk, Netherlands) containing 10% fetal bovine serum
supplemented with penicillin and streptomycin (10,000 U/ml) at
37uC under 5% CO2. NT2 cells were passaged at 90% confluence
while NCCIT were passaged at 80% confluence. Briefly, cells were
seeded at the density of in 75 ml flasks. Seeding ratio for NT2 cells
and NCCIT cells were 1:3 and 1:5 respectively. Incubated cells
were harvested with trypsin-EDTA, washed with PBS, centrifuged
and resuspended in DMEM medium. Approximately 8000 cells
were used to make cytospins. 100 ml of counted cells (diluted in
medium) were put on glass slides. In order to put cells on glass
slides, Cytospin chambers were used. The slides were set into
cytospin machine for 10 min and 500 rpm. Then chambers were
removed and glass slides were air dried for at least 2 hours and
were stored at 220uC.
siRNA transfection for SOX2 and OCT3/4
NCCIT cells were transfected with siRNA based SOX2
(s13294; Ambion/Invitrogen, Breda, the Netherlands), siRNA
against OCT3/4 (Qiagen,Manchester, UK) [41] and Silencer
Negative Control siRNA (4611, Life technologies Europe BV,
Bleiswijk, Netherlands) using Lipofectamine 2000 (Life technolo-
gies Europe BV, Bleiswijk, Netherlands) in 24 well-plates (Greiner
bio-one/Germany) according to the manufacturers’ protocol. The
transfection ratio (siRNA:Lipofectamine) was 1:2.
Protein Isolation and Western blotting analysis
Isolation of protein and Western blotting analysis were
essentially performed as previously described [42]. The antibodies
are described in Immunohistochemistry (see below). The dilution
of antibodies used for western blot was 1:1000 for both OCT3/4
and SOX2 antibodies. In addition, mouse monoclonal beta-actin
(clone AC-15; Sigma Aldrich, St Louis, MO, USA) was used. The
blocking solution used was milk (1%). Binding of the primary
antibodies was visualized by using IRDYe donkey anti-mouse or
donkey anti-goat secondary antibodies and the blots were scanned
on the Odyssey infrared imaging system (from LI COR
Biosciences, NE, USA).
Immunohistochemistry (IHC)
Staining was performed on cell lines as well as FFPE tissues.
Unfixed cells were incubated for 1 hour at room temperature with
the primary antibodies. Formalin-fixed paraffin-embedded (FFPE)
tissues (4 mm thick sections) were pretreated by antigen retrieval
(Tris (0.001m/EGTA (0.01 m) PH 9.0) [43] after deparaffiniza-
tion and blocking of the endogenous peroxidase with H202 (3%)
(Merck-KG9A; 108597, Darmstadt, Germany). Endogeneous
biotine is blocked by Avidin-Biotin blocking kit (Vector, SP-
2001, Burlingame, CA 94010, USA). Incubated overnight at 4uC.
Antibodies used were SOX2 (1:250, AF2018; R&D System, USA),
OCT3/4 (sc-5279; 1:350; sc-Santa Cruz Biotechnology, Santa
Cruz, CA, USA), Ki67 (1:50, A047; Dako, CA, USA) and Caspase
3 (1:500, 9579; Cell Signaling).
Visualization was performed by using horseradish peroxidase
avidin-biotin complex (Vectastain, Vector SP-2001, Burlingame,
CA 94010, USA) and DAB/H202 as substrate. For negative
controls, primary antibody was omitted, resulting in complete
absence of signals.
Percentage of knock-down
Cells were harvested by trypsinization and analyzed for knock-
down of the proteins under investigation using IHC on cytospins
(see below). Percentage of positive cells for each gene was
calculated by counting five different regions on the cytospin in
which each region contained 100 cells, therefore, the total number
of counted cells were 500 cells. The cells were defined as positive
when the color brown was above the background color and cells
with color blue above the background level were counted as
negative for antibody used. This method has been tested and
published in [33].
SOX2 and EC
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Cell viability test
Cell death induced by siRNA transfection was evaluated by
trypan blue exclusion. Briefly, NCCIT cells were harvested after
48 h, 54 h and 60 h after siRNA transfections. Cells were washed
with PBS and resuspended in 100 ml PBS. After mixing with
100 ml 0.8% trypan blue cells were calculated as the number of
blue cells/total number of cells.
Flow cytometry
Propidium Iodide. In order to measure the percentage of
live and dead cells, Propidium Iodide (PI) assay was used. Briefly,
cell pellets were resuspended in 500 ml of PBS. Cells were fixed by
adding 5 ml of 70% cold ethanol. Then the cell suspension was
centrifuged at 400 g for 5 min and the supernatant was removed.
Cell pellet was washed with PBS and resuspended in 1 ml of PI
staining solution (50 mg/ml) according to the standard protocol.
Cells were incubated for at least 30 min at room temperature in
the dark to be analyzed by flow cytometry using FACSAria III
machine using 488-nm laser line for excitation.
AnnexinV. Percentage of apoptotic cells was measured using
BD Pharmingen FITC AnnexinV apoptosis detection kit I
(556547; Erembodegem, Belgium) according to the manufactur-
ers’ protocol. Hoechst 33258 (H3569), (Molecular probe/Invitro-
gen, Leiden, the Netherlands) was used at the concentration of
1 mg/ml. Briefly, harvested cells (1610 ‘5) were washed with PBS,
centrifuged and resuspended in Annexin buffer provided with the
kit. The final concentration used for Annexin was 0.5 mg/ml. Cells
were analyzed by FACSAria III machine.
In Situ hybridization
Fluorescent in situ hybridization (FISH) was performed with
probe mapped to chromosome 3 band 26.33 (RP11-43F17) for
SOX2 detection. In addition, an OCT3/4 specific probe was used
(RP11-1058J10). In addition to this specific region, a probe
mapped to centromeric region of chromosome 12 was assessed as
control [44]. Briefly, FFPE tissue section of 4 mm thickness were
deparaffinized, pretreated in a 0.01 M Sodium citrate solution
under high pressure in pressure cooker, subsequently with pepsin
(4.000 U) at 37uC followed by washing and dehydration. Probes
were labeled by nick-translation, according to standard proce-
dures, either with dioxigenin-11-dUTP (Roche, Manheim,
Germany) or biotin-16-dUTP (Roche, Manheim, Germany), and
applied in 10-15 ml hybridization mixture on the tissue slides. The
probes were denatured together with the target by placing the slide
for 10 min on the 80uC oven. After hybridization overnight at
37uC, the slides were washed stringently and the hybrids were
detected by FITC-conjugated sheep-anti-digoxigenin (Roche,
Manheim, Germany) and CYE3-conjugated avidine (Jackson
Immuno research laboratories, Cambridgeshure, UK) Results
were studied with a fluorescent microscope LSM700 Zeiss. Cells
were pretreated in 220uC methanol/acetone for 20 min and the
rest of the procedure for FISH on NCCIT cells was the same as
above mentioned with omitting of the high pressure treatment.
Xenografts generation
The NMRI/Nu-Nu strain of immune-compromised female
mice (Mus musculus), aged 6–8 weeks (Charles River Laboratories,
Wilmington, Massachusetts, USA) was used in this study. The
animals were housed in the individually ventilated cages with
sterile bedding, water, rodent chew feed and air. Experiments
were carried out in accordance with the ARRIVE guidelines [45]
and the animal research protocol was approved by the Institu-
tional Animal Ethical Committee (DEC), Erasmus University
Medical Center, Rotterdam, the Netherlands.
Six mice were used. The mice were anesthetized by the
exposure to 2% isoflurane (Pharmachemie BV, Haarlem, The
Netherlands) and placed ventral side up on a pre-warmed injecting
pad. Approximately 10–12 million cells from each cell line
suspended in 200 ml fresh culture medium with 20% serum were
implanted under the skin with a 1-cc syringe and 24-gauge needle.
Two week after implantation, xenograft tumor growth was
checked by palpation and the size of xenografts was measured
using a vernier calliper [xeno-tumor size (mm2) = length x width]
twice a week and the mice were followed for a total period of
maximal 12 months until they were sacrificed. For ethical reasons,
primary xenograft tumors reaching the size of 225 mm2 were
taken from study and sacrificed. The primary tumors were
preserved by direct freezing in liquid nitrogen as well as by fixation
in 10% formalin solution (Sigma-Aldrich, St. Louis, Missouri,
USA) for subsequent histological analyses.
Cultivation of NCCIT sub-lines, N-NCCIT and N2-NCCIT
N-NCCIT and N2-NCCIT were re-cultured similarly as
described for the original NCCIT cell line.
Results
OCT3/4 and SOX2 in Embryonal Carcinoma (EC) cell lines
SOX2 amplification confirmed in NCCIT cells. Our
previous genome wide copy number investigation of multiple
EC cell lines showed a specific amplification at the long arm of
chromosome 3, band q23, including the SOX2 gene locus only in
the NCCIT cell line [34]. The borders were defined as
177.604.206 bp (detected by RP11-71G7 probe) until
184.060.761 bp (detected by RP11-553E4 probe), encompassing
a region of about 6.4 Mb. Various genes are mapped to this
genomic fragment including SOX2 (Figure S1A & B). To
investigate the pattern of expression of all genes within the
amplified region in a series in primary GCC, including multiple
pure EC, high throughput Affymetrix expression data analysis was
performed, and compared to SE. The results showed a significant
difference between the expression of SOX2 in EC and SE, being
high versus low in expression respectively, which is in line with
previous findings [19]. In total, 13 genes were analyzed in this
region in which three genes, including SOX2, showed a significant
difference between EC and SE (Figure 1A). Although there are
other candidate genes within the amplified region, due to critical
role of SOX2 in early development in close connection with
OCT3/4 and its diagnostic value in the diagnosis of GCC, SOX2
was selected for further investigations. To verify the presence of
SOX2 amplification in NCCIT, DNA FISH was performed using
a verified probe for SOX2 gene (labeled with biotin). A
centromere 12 (C12) specific probe (labeled with digoxigenin)
was used in a double FISH experiment as control for copy number
changes. The frequency of the signals obtained for SOX2 and C12
confirmed the amplification of SOX2, suggested to be at a single
chromosome (Figure 1B).
Silencing OCT3/4 and SOX2 in NT2. To investigate the
effect of reduced levels of OCT3/4 and SOX2 in the NT2 cell
line, representative for pluripotent EC, without amplification of
SOX2, siRNA-based OCT3/4 and SOX2 inhibition was
performed. Based on the results obtained, specific siRNAs were
chosen for further experiments (boxed in Figure S2). Because of
the time effects, cells obtained 72 h after transfection were chosen
for subsequent analysis. Both OCT3/4 and SOX2 RNA- knock-
down in the NT2 cell line under these conditions have previously
SOX2 and EC
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resulted in defined induction of differentiation as described before
[33]. In the mentioned study, as a result of OCT3/4 downreg-
ulation, expression of pluripotency genes such as OCT3/4, SOX2,
NANOG and LIN28 were down regulated and expression of some
differentiation genes such as OTX1, PAX-6 (ectoderm), HAND1,
BRACHYURY, MYOD1 (mesoderm), AFP, GATA4 (endoderm)
and BMPR2 (germ cell) were upregulated.
Additionally, using the selected siRNAs, the microarray data on
NT2 cells with OCT3/4 and SOX2 knockdown compared to the
negative control NT2, showed 90% downregulation for OCT3/4
and 67% SOX2 knock-down on the RNA level 72 hours after the
incubations. For microarray analysis Sentrix human6 BeadchipV3
was used. According to the array data, the number of intensity for
OCT3/4 in the negative control NT2 was 8524 which decreased
to 865 in the OCT3/4 knockdown NT2. SOX2 intensity in the
negative control NT2 was 1460 which in SOX2 knock-down cells
decreased to 479.
Silencing OCT3/4 and SOX2 in NCCIT. To investigate
the effect of reduced levels of OCT3/4 and SOX2 in the NCCIT
cell line, as done in the NT2 cell line, the selected siRNAs for
OCT3/4 and SOX2 (see above) were transfected, and the cells
were investigated at three different time points (48, 48+6 h and
48+12 h). Use of each siRNA specifically led to a down-regulation
of OCT3/4 and SOX2 protein expression in NCCIT. The
percentage of positive cells for these proteins was measured in
negative control cells and cells transfected with siRNAs, by
immunohistochemistry, shown to be an informative method for
analysis [33] Additional data are shown in Figure S3. The results
indicate that the expression level of OCT3/4 and SOX2 protein
expression were reduced significantly in time (Figure 2A).
OCT3/4-down-regulation in NCCIT results in loss of
pluripotency. To investigate the effect of OCT3/4 down-
regulation on the identity of the NCCIT cells, expression level of a
selected panel of genes representative for pluripotency and
differentiation (for all embryonic germ layers: mesoderm, endo-
derm and ectoderm) was measured using q-RT-PCR, as reported
before [33]. As in the NT2 cells, OCT3/4 down-regulation
resulted in differentiation, demonstrated by loss of the pluripo-
tency factors (OCT3/4, NANOG and LIN28) and up-regulation of
some differentiation genes, including OTX1 (ectoderm), brachyury
and HAND1 (mesoderm), and LAMB1 (endoderm) (Figure 2B).
The details on qRT-PCR panel has been described in [46]. No
morphological changes were been observed in the cells under
investigation.
SOX2-siRNA caused major apoptosis in NCCIT. As
reported for OCT3/4, reduction of SOX2 expression in NT2
resulted in induction of differentiation [33]. In contrast, in the
NCCIT cell line SOX2 reduction did not result in differentiation,
but instead, it caused a progressive loss of cells in time (48, 48+6,
48+12 and 72 hours after transfection). Cell death was obvious
after 54 hours and prominent at 60 hours. Because at the last time
point, almost no viable cells were present, no further analysis could
be done including expression profiling. Using Trypan blue
staining, the presence of live cells was measured at each time
point (Figure 2C). The results demonstrate at the latest time point
after transfection a progressive and significant effect of SOX2 and
OCT3/4 reduction on the amount of living cells in time,
indicating only 20% living cells in the SOX2 reduced cells and
50% living cells in the OCT3/4 reduced cells. To investigate the
effect of SOX2 and OCT3/4 down-regulation on proliferation,
immunohistochemical staining was performed for Ki67 on
cytospin slides at the latest time point (60 h). The results
(Figure 2D) demonstrate that OCT3/4, inducing loss of pluripo-
tency (see above), also resulted in a decrease in proliferation status
compared to the negative siRNA control and untreated cells for
about 50%. The effect of SOX2 reduction was even more severe,
resulting in about 10% positive cells (p,0.01). Subsequently, we
investigated whether loss of cells was also the result of increased
apoptosis, for which various approaches were used. These include
immunohistochemistry for the apoptosis marker Caspase 3
Figure 1. Gene expression within the amplified region. A) Expression histogram indicating the relative expression of genes mapped within the
amplified region in a series of SE and EC. The stars indicate genes significantly differentially expressed between SE and EC (according to Mann
Whitney U test). Most of the genes are represented by multiple specific probes; B) DNA-FISH result for SOX2 in NCCIT cells. A centromere 12 (C12)
specific probe is used as control. Red dye (Cye3) shows SOX2 probe. For C12 probe green dye (FITC) is used. The blue background color is DAPi.
Multiple red spots for SOX2 are detectable in each cell containing two green spots for C12, indicating SOX2 amplification. Magnification used was
630x. DNA-FISH was performed on cut tissue section with a thickness of 4 micron. This results in possible heterogeneity of the probe sizes detected.
This issue was not a limitation as the purpose of this experiment was to determine the copy numbers and the size or intensity of the region. The FISH
(BAC) probes were ordered at BACPAC Resources Center (BPRC) online:bacpac.chori.org. They were verified and confirmed at the department of
genetics.
doi:10.1371/journal.pone.0083585.g001
SOX2 and EC
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Figure 2. OCT3/4 and SOX2 knockdown in NCCIT. A) Percentage of positive cells for OCT3/4 and SOX2 in cells with reduced OCT3/4 and SOX2
levels compared to cells transfected with control siRNA in the NCCIT cells in three different time-points post transfection based on
immunohistochemistry; The controls are set to 100 in all cases. B) Relative expression pattern of 32 genes representing targets for pluripotency
and differentiation (ectoderm, mesoderm and endoderm). The expression levels are normalized based on the housekeeping gene HPRT; C)
Percentage of living NCCIT cells with reduced level of OCT3/4 and SOX2 compared to cells transfected with control siRNA at each time point based on
SOX2 and EC
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(Figure 2E). Positive staining was found predominantly and
significantly in the cells with SOX2 inhibition, especially at the
60 hours time point (p = 0.04). In contrast, inhibition for OCT3/4
resulted in less than 4% apoptotic cells. This pattern was
confirmed by FACS analysis using Propidium Iodide (PI) exclusion
test and Annexin V staining (Figure 2F, G). These data
demonstrate that the major decrease in the amount of living
NCCIT cells due to reduced SOX2 expression is explained by
induction of apoptosis, as determined by independent methods.
N-NCCIT and N2-NCCIT xenografts show a consistent
positive expression for SOX2. It is known that NCCIT has
the capacity to differentiate [31,47], in line with the results
obtained from the OCT3/4 inhibition experiments (see above).
SOX2 is found to be an absolute marker for EC in combination
with OCT3/4, although it can also be found more heteroge-
neously in differentiated components, especially teratoma [19]. In
the context of the induction of apoptosis by means of SOX2
suppression in NCCIT, it is interesting to investigate whether
NCCIT cells grown as a xenograft in vivo remains SOX2 positive
throughout, in spite of possible differentiation. To answer this
question, multiple mice xenografts were generated from the
parental NCCIT cell line (referred to N- and N2-NCCIT). The
established tumors were characterized, and a sub-line was
subsequently cultured continuously in vitro. The N-NCCIT sub-
line was tested for OCT3/4 and showed positive staining (Figure
S4). The in vivo tumors were tested for SOX2 and OCT3/4. The
overall pattern (representative examples shown in Figure 3)
indicated that in spite of morphological induction of differentia-
tion, supported by loss of OCT3/4 by immunohistochemistry, this
was not accompanied by loss of the expression of SOX2. In other
words, SOX2 remained positive in all components of the tumors.
Detection of amplification for SOX2 and OCT3/4 in EC
Because SOX2 is amplified in the EC cell line NCCIT, with a
functional effect on survival, it is of interest to check whether
primary GCC, have SOX2 amplification. Particularly, the so-called
nullipotent EC might be of interest to be investigated, although
this component might also be present in mixed nonseminomas,
i.e., tumors with a histologically mixed composition. A series of 12
pure EC and 34 mixed GCCs including an EC component were
studied using the double FISH method (see above). No amplifi-
cation for SOX2 or OCT3/4 (i.e. more than 6 copies) was found in
the cases investigated (shown in Figure S5).
Discussion
Pluripotent stem cells have been isolated from a variety of
human and mouse sources as models to investigate processes
involved in early embryonal development [48,49]. Two of the
well-studied cell types are ES cells derived from the inner cell mass
of blastocyst-stage embryos and EC cells, the nonseminomatous
stem cells of GCC [49,50]. By definition, pluripotent stem cells
have extensive self-renewal capacity and the ability to differentiate
into wide variety of cell types [48,49,51]. In fact EC cells derived
from the progenitor of the germ line are a malignant equivalent of
ES cells [52], thus they provide a good model to study early
embryonal development as well as tumorigenesis [49].
OCT3/4 and SOX2 are transcription factors essential to the
pluripotent and self-renewing phenotypes of ES cells. These
master ES cell pluripotency factors are highly expressed in EC
[19,53]. Representative cell lines of EC which are capable of
differentiation (NT2, NCCIT, 2102Ep) have been generated and
extensively used for studies [30,31,47,50]. Based on our molecular
data derived from array CGH data, the NCCIT cell line, derived
from an extra-gonadal GCC, shows a restricted amplification of
Trypan blue measurement; D) Percentage of positive NCCIT cells for Ki67 in untreated cells, cells transfected with control siRNA and cells with
reduced levels of OCT3/4 and SOX2 at 48+12 h post transfection; E) Percentage of positive cells for Caspase 3 in untreated NCCIT cells, Cells
transfected with control siRNA show a reduced level of OCT3/4 and SOX2 at all three time points after the transfection; F) FACS analysis with
Propidium Iodide staining in cells transfected with control siRNA, cells transfected with SOX2 and OCT3/4 siRNA at 60 h post transfection. NCCIT cells
transfected with control siRNA show the presence of 78% living cells, while cells transfected with SOX2 siRNA show 51% living cells, NCCIT cells with
OCT3/4kd show 62% live cells. G) Annexin V assay results in cells with siRNA control and cells with reduced SOX2 and OCT3/4 at 60 h after
transfection. In the control, percentages of living-annexin negative cells are 89.6%, while dead-annexin positive cells are 12.2%. In SOX2kd cells, the
amount of living-annexin negative cells is 57.5% while the amount of dead-annexin positive cells is 17.2%. In cells transfected with OCT3/4 siRNA,
living-annexin negative cells are 68.3% while dead-annexin positive cells are 12.8%. The differences between the percentages of live and dead cells in
all experiments are due to using independent and various methods in order to prove apoptosis and different sensitivity of the materials and methods
used. As it is demonstrated, OCT3/4 knock-down also induces apoptosis, however, this effect is not as dramatic as SOX2 knock-down. The FACS
analysis were performed in triplicate.
doi:10.1371/journal.pone.0083585.g002
Figure 3. Immunohistochemistry for SOX2 and OCT3/4 on
nude mice xenografts of NCCIT. Images A, B and C belong to N-
NCCIT; D, E and F belong to N2-NCCIT. A & D) H & E staining
demonstrates the histological composition, showing regions with
differentiation (indicated with a circle); B & E) Staining for OCT3/4
showing the presence of heterogeneity, showing undifferentiated
(positive) and differentiated (negative) cells; C & F) Staining for SOX2
shows that the malignant cells are consistently positive, in spite of the
presence or absence of OCT3/4.
doi:10.1371/journal.pone.0083585.g003
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the 3q23 region. This region contains SOX2, amongst many other
genes. Here we demonstrate that indeed SOX2 maps within the
minimal region of overlap of the amplification. This triggered a
more detailed analysis of the role of SOX2 in this cell line
compared to an EC cell line without such a genomic amplification.
In fact, SOX2 amplification and its pathogenic role association
with oncogenesis have been reported in human lung squamous cell
carcinoma [54]. In addition, targeting SOX2 in breast cancer cell
lines have shown that siRNA-mediated knock-down of SOX2
resulted in cell cycle arrest by down-regulation of Cyclin D1 and
this arrest in cell cycle was accompanied by an inhibition of tumor
cell proliferation in xenograft models [18]. Most recently, it has
been reported that inhibition of SOX2 might be of therapeutic
potential for EC [29]. In that particular study, SOX2 down-
regulation in the EC cell line NEC8, when established in vivo,
induced tumor growth suppression in case of a limited tumor size.
In contrast, down-regulation showed no effect on progression in
case of a tumor of larger size. This is likely related to loss of SOX2
expression to some extent and differentiation. This study indicates
that suppression of the SOX2 expression might be useful to block
cell proliferation in early stage EC. Interestingly, as a result of our
array CGH study on multiple EC cell lines, NCCIT cell line
showed amplification of the long arm of chromosome 3, band q23
including the SOX2 gene locus [34].
Unlike the majority of GCC cell lines which are derived from
testicular cancers, NCCIT is derived from an extragonadal
mediastinal GCC. In 1988, NCCIT was established as an in vitro
cell line, composed of developmentally pluripotent cells capable of
somatic and extra-embryonic differentiation. Nude mouse-xeno-
grafts of NCCIT contained foci of EC, yolk sac tumor, immature
somatic tissues, and trophoblastic giant cells indicating that this
cell line is indeed developmentally pluripotent [47]. In 1993,
retinoic-induced differentiation of NCCIT into all three embry-
onic germ layers and extra-embryonic cell lineages was reported,
and in fact, it was suggested that the parental NCCIT cells show
characteristics intermediate between SE and EC [31]. We
investigated the effect of OCT3/4 and SOX2 down-regulation
in NCCIT. The results demonstrate that inhibition of OCT3/4
resulted in loss of pluripotency and only partial apoptosis, while
inhibition of SOX2 led to extensive cell death. This suggests that
survival of NCCIT is dependent on the presence of SOX2
expression, referred to as oncogene-dependence [55]. This was
supported by various methods and read out systems. As a control,
inhibition of OCT3/4 and SOX2 was done similarly in the NT2
cell line, which showed induction of differentiation under the
experimental conditions applied [33]. The next step in our study
was to investigate the potential of the NCCIT cells to undergo
differentiation in vivo. Therefore multiple xenografts were gener-
ated. Interestingly, in spite of induction of partial differentiation,
supported by loss of OCT3/4, all tumor cells remained positive for
SOX2. This is in line with the hypothesis that differentiation is
possible, as found in the in vitro experiments, even in spite of SOX2
amplification. The lineages formed are selected by continuous
expression of SOX2 [56]. In this context the potential use of
inhibition of SOX2 in a clinical setting, should be considered
carefully because down-regulation of SOX2 might result in the
induction of differentiation, leading to potentially highly metastatic
clones.
The absence of SOX2 amplification in a series of in vivo pure EC
and EC containing mixed nonseminomas, suggest that SOX2
oncogene dependence, at least due to gene amplification, is not a
frequent mechanism in GCC, which questions indeed the
approach of targeted therapy in a clinical setting. In this context
it might be of interest to check whether the NEC8 cell line
contains SOX2 amplification [29]. In addition,as the number of
EC tumors investigated for SOX2 amplification (50 samples) is not
a large number, there is a possibility that SOX2 amplification is
present in a limited number of cases.
The presence of SOX2 amplification in the NCCIT cell line
might be explained by involvement of other mechanisms, like
absence of a functional p53 status. The importance of the
connection between pluripotency genes, ES pluripotency stem cell
miRs and wildtype/mutant p53 in the pathogenesis of GCC has
been previously described [57]. It has been shown that p53
activates expression of miR-34a and miR-145, which in turn
repress key stem cell factors such as OCT3/4 and SOX2 to
prevent self-renewal and promote differentiation [58] (Figure 4).
miR-145 regulates such activities by activation of WNT signaling
pathway via intracellular localization of b-catenin [59]. Indeed,
earlier miR profiling experiments demonstrate that miR-34a is not
present in NCCIT, and miR-145 shows a low level of expression
[60]. This might be due to the mutated p53 status, resulting in loss
of inhibition of SOX2 expression. Additionaly, in this context it
was shown that miR-371-3 which is thought to mimic the role of
mutant p53 in GCC is expressed at low levels in NCCIT with
mutant p53 and in NT2 with low expression level of wild type p53
[35].
Interestingly, NT2 and TCam2 (another GCC cell line with
seminomatous characteristics) show similar corelation patterns
between p53 status and expression levels of miR-34a and miR-
145. NT2 has a low level of wild type p53 as well as miR-34a and
miR-145, with a high level of SOX2. In contrast, the TCam2 cells
have a relatively normal level of wild type p53, and a high level of
miR-34a and miR-145. Indeed, as expected no SOX2 is
expressed, in line with the seminoma type of cells, linked to
expression of SOX17 instead of SOX2. This justifies the absence
of WNT signaling in TCam2, since SOX17 is known to suppress
this particular pathway [61,62]. This connection between p53, its
downsteam targets regulating the expression of pluripotency
factors such as SOX2 is of interest since most GCC patients have
low levels of wild type p53, and p53 mutations are rarely observed
[63]. We have shown that wild type p53 status is related to the
Figure 4. Schematic representation of the hypothetical indirect
regulation of SOX2 by p53 status. Wild type p53 results in
induction of expression of miR-145 and miR-34a. Subsequently, miR-34a
and mir-145 down-regulates pluripotency genes, including SOX2, the
latter via Wnt signaling.
doi:10.1371/journal.pone.0083585.g004
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response of GCC to DNA damaging agents, including cisplatin
[63]. This can elegantly explain why GCC show such an
exceptional sensitivity to DNA damaging agents [64].
Most recently it has been shown that site-specific phosphory-
lation of OCT3/4 regulated by AKT, promotes stemness of EC
cells (i.e., NCCIT) compared to ES cells [65]. Presence of this site-
specific phosphorylation promotes release of the OCT3/4 protein
from the AKT1 promoter, resulting in induced expression, which
will lead to suppression of apoptosis, and simultaneously, enhances
capacity of OCT3/4 to form a complex with NANOG and
SOX2, promoting pluripotency. This additional effect promotes
tumorigenic capacity of EC compared to ES, which might be of
interest for further investigation.
In conclusion, these data shed novel light on the role of ES cell
pluripotency factors in NCCIT (as an EC cell line) which can
reflect the role of these factors, particularly SOX2 and its
dependence in relation to differentiation, in the etiology of EC
and regulation of stem cell differentiation.
Supporting Information
Figure S1 Genomic region of amplification. A) UCSC
genome browser (version hg19) representation of the genomic
region of amplification at the long arm of chromosome 3, band
q23.33, in NCCIT cells. The borders are 177.604.260 bp and
184.060.761 bp (encompassing a region of about 6.4 Mb). The
genes mapped to this region are shown including SOX2 locus; B)
Array CGH result, the region of amplification in chromosome 3q
is indicated in red circle, the borders are defined between the
probes RP11-71G7 and RP11-553E4, respectively. The y axis
indicates the unique position number based on probe distribution
and the X axis shows a log ratio compare to normal sample.
(TIF)
Figure S2 Western blot analysis of down-regulation of
OCT3/4 and SOX2 in NT2 cells at various time points
(24, 48, 72, 96 and 120 hours). A) NT2 cells are transfected
with two independent OCT3/4 siRNAs (‘‘Matin’’ and ‘‘Hay’’),
two independent b-actin siRNAs and negative control siRNA.
OCT3/4 ‘‘Hay’’ is selected for further experiments. B) NT2 cells
are transfected with three independent SOX2 siRNAs (13294,
13295 and 13296), one b-actin siRNA and negative control
siRNA. SOX2-13294 siRNA is selected for further experiments.
The selected siRNAs are boxed in red within the Figure. These
conditions showed the most profound down-regulation of
expression at the protein level (over 90%) (In 72 h incubation,
SOX2- siRNA 13295 and 13296 have been switched).
(TIF)
Figure S3 Silencing OCT3/4 and SOX2 in NCCIT.
Examples of immunohistochemistry on cytospin slides.
A) SOX2 staining in negative control NCCIT. B) OCT3/4
staining in negative control NCCIT. C) SOX2 staining in
SOX2kd NCCIT cells. D) OCT3/4 staining in OCT3/4kd
NCCIT cells.
(TIF)
Figure S4 OCT/4 staining for cultivated N-NCCIT cells.
Brown colored cells show 95% positive staining for OCT3/4 in
cultivated N-NCCIT cells (sub-line of NCCIT cells). Magnifica-
tion used was 100x.
(TIF)
Figure S5 Examples of FISH for SOX2 on EC tumors.
Red dye (Cye3) shows SOX2 probe. For C12 probe green dye
(FITC) is used. Not more than two copies of SOX2 probe in each
nuclease are detected in these tumors.
(TIF)
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